Used in the treatment of chronic lymphocytic leukemia (CLL) and other B-cell malignancies by targeting CD52, a protein highly expressed on the surface of malignant lymphocytes. It mediates cell lysis through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Investigated for use in autoimmune disorders due to its ability to deplete lymphocytes, contributing to immune system modulation. Also serves as a reference standard in bioanalytical assays for evaluating biosimilars and immunoassay development.